Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-methyl-1,4-androstadiene-3,17-dione
2. Sh 489
3. Sh-489
4. Sh489
1. 96301-34-7
2. Atamestane [inn]
3. 1-methylandrosta-1,4-diene-3,17-dione
4. Sh-489
5. 62ga3k28b6
6. Atamestanum [latin]
7. Atamestano [spanish]
8. Atamestano
9. Atamestanum
10. (8r,9s,10s,13s,14s)-1,10,13-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3h-cyclopenta[a]phenanthrene-3,17(6h)-dione
11. Ccris 6528
12. Unii-62ga3k28b6
13. Biomed-777
14. 1-methyl-1,4-androstadiene-3,17-dione
15. Androsta-1,4-diene-3,17-dione, 1-methyl-
16. Atamestane [who-dd]
17. Schembl59128
18. Chembl2105987
19. Dtxsid30869268
20. Zinc4214890
21. Db12194
22. (8r,9s,10s,13s,14s)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione
23. 1-methyl-androsta-1,4-diene-3,17-dione
24. 1-methyl-androsta-1,4 -diene-3,17-dione
25. Q4812727
| Molecular Weight | 298.4 g/mol |
|---|---|
| Molecular Formula | C20H26O2 |
| XLogP3 | 2.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 298.193280068 g/mol |
| Monoisotopic Mass | 298.193280068 g/mol |
| Topological Polar Surface Area | 34.1 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 626 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
ABOUT THIS PAGE
A Atamestane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atamestane, including repackagers and relabelers. The FDA regulates Atamestane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atamestane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Atamestane supplier is an individual or a company that provides Atamestane active pharmaceutical ingredient (API) or Atamestane finished formulations upon request. The Atamestane suppliers may include Atamestane API manufacturers, exporters, distributors and traders.
click here to find a list of Atamestane suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atamestane DMF (Drug Master File) is a document detailing the whole manufacturing process of Atamestane active pharmaceutical ingredient (API) in detail. Different forms of Atamestane DMFs exist exist since differing nations have different regulations, such as Atamestane USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atamestane DMF submitted to regulatory agencies in the US is known as a USDMF. Atamestane USDMF includes data on Atamestane's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atamestane USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atamestane suppliers with USDMF on PharmaCompass.
Atamestane Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atamestane GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atamestane GMP manufacturer or Atamestane GMP API supplier for your needs.
A Atamestane CoA (Certificate of Analysis) is a formal document that attests to Atamestane's compliance with Atamestane specifications and serves as a tool for batch-level quality control.
Atamestane CoA mostly includes findings from lab analyses of a specific batch. For each Atamestane CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atamestane may be tested according to a variety of international standards, such as European Pharmacopoeia (Atamestane EP), Atamestane JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atamestane USP).
LOOKING FOR A SUPPLIER?
